Surovatamig for Chronic Lymphocytic Leukaemia

(SOUNDTRACK-C1 Trial)

This trial tests a new treatment called Surovatamig for individuals with Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL) who possess a specific genetic marker known as unmutated IGHV. The study aims to determine if Surovatamig, administered as a subcutaneous injection, is safe and effective as a follow-up treatment after initial therapy. Participants will either receive varying doses of Surovatamig or be observed for a period. This trial suits those diagnosed with CLL or SLL, who have completed their first round of treatment, and have the genetic feature unmutated IGHV. As a Phase 3 trial, it represents the final step before FDA approval, offering participants a chance to contribute to potentially groundbreaking treatment advancements.

The trial information does not specify whether you need to stop taking your current medications. It's best to discuss this with the trial coordinators or your doctor.

Research has shown that Surovatamig has been tested in people before. In these studies, the treatment proved generally safe, with most participants experiencing no serious side effects. The most common side effects were mild, such as redness or swelling at the injection site, which is typical for subcutaneous treatments.

Another study on its use for different conditions also found Surovatamig to be mostly safe, with serious side effects being rare. This suggests that Surovatamig might be well-tolerated by people with Chronic Lymphocytic Leukemia.

Researchers are excited about Surovatamig for chronic lymphocytic leukemia (CLL) because it offers a new approach to treatment. Unlike traditional therapies such as chemotherapy and targeted drugs like ibrutinib or venetoclax, Surovatamig is administered subcutaneously, which can be more convenient for patients compared to intravenous or oral options. Additionally, it works by a novel mechanism that targets specific pathways involved in CLL, potentially leading to more effective control of the disease. This unique delivery method and mechanism of action make Surovatamig a promising option that could improve patient outcomes.

Research has shown that surovatamig may help treat certain blood cancers. One study found that patients who had already received CD19-targeted therapy had a 67% response rate with one dose of surovatamig and a 100% response rate with a higher dose. Another study on patients with B-cell non-Hodgkin lymphoma reported a 96% response rate, with 85% of patients achieving complete remission. This trial will evaluate different doses of surovatamig for patients with Chronic Lymphocytic Leukemia (CLL), including those with unmutated IGHV, to gather specific data on its effectiveness for CLL.²³⁴⁵⁶